Attached files

file filename
10-Q - QUARTERLY REPORT - TherapeuticsMD, Inc.txmd-10q_033113.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - TherapeuticsMD, Inc.ex31-2.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex32-1.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - TherapeuticsMD, Inc.ex31-1.htm
EX-10.32 - CONSULTING AGREEMENT WITH SANCILIO AND COMPANY, INC. - TherapeuticsMD, Inc.ex10-32.htm
EX-10.31 - AGREEMENT TO FORFEIT NON-QUALIFIED STOCK OPTIONS - TherapeuticsMD, Inc.ex10-31.htm
EXCEL - IDEA: XBRL DOCUMENT - TherapeuticsMD, Inc.Financial_Report.xls


EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of TherapeuticsMD, Inc. (the "Company") on Form 10-Q for the quarterly period ended March 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 
(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and

 
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
/s/ Daniel A. Cartwright
 
Daniel A. Cartwright
 
Chief Financial Officer
 
May 10, 2013
 
 
A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.